About Aviceda Therapeutics
Aviceda Therapeutics is a company based in Cambridge (United States) founded in 2018 by Christopher Scott, Michael Tolentino, Derek Kunimoto, and Mohamed Genead.. Aviceda Therapeutics has raised $254.66 million across 5 funding rounds from investors including Marshall Wace, abrdn and Orbimed. Aviceda Therapeutics offers products and services including Selective Ligands and Pipeline Programs. Aviceda Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others.
- Headquarter Cambridge, United States
- Founders Christopher Scott, Michael Tolentino, Derek Kunimoto, Mohamed Genead
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$254.66 M (USD)
in 5 rounds
-
Latest Funding Round
$207.5 M (USD), Series C
Dec 17, 2024
-
Investors
Marshall Wace
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aviceda Therapeutics
Aviceda Therapeutics offers a comprehensive portfolio of products and services, including Selective Ligands and Pipeline Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Compounds designed for precise immune modulation in inflammation and diseases.
Development of therapies targeting immune cells for various immunologic conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Aviceda Therapeutics
Aviceda Therapeutics has successfully raised a total of $254.66M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $207.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series C — $207.5M
-
First Round
First Round
(16 Sep 2020)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Series C - Aviceda Therapeutics | Valuation | Omega Funds | |
| May, 2024 | Amount | Series C - Aviceda Therapeutics | Valuation |
investors |
|
| May, 2023 | Amount | Series B - Aviceda Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aviceda Therapeutics
Aviceda Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Marshall Wace, abrdn and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Jeito Capital is focused on financing medical innovation globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aviceda Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aviceda Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aviceda Therapeutics Comparisons
Competitors of Aviceda Therapeutics
Aviceda Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Biogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aviceda Therapeutics
Frequently Asked Questions about Aviceda Therapeutics
When was Aviceda Therapeutics founded?
Aviceda Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Aviceda Therapeutics located?
Aviceda Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Aviceda Therapeutics?
Mohamed Genead is the current CEO of Aviceda Therapeutics. They have also founded this company.
Is Aviceda Therapeutics a funded company?
Aviceda Therapeutics is a funded company, having raised a total of $254.66M across 5 funding rounds to date. The company's 1st funding round was a Series B of $15.61M, raised on Sep 16, 2020.
What does Aviceda Therapeutics do?
Aviceda Therapeutics was founded in 2018 and is based in Cambridge, United States. Biotherapeutics targeting glycol-immune diseases are developed, with a pipeline focused on eye diseases, fibrosis, neurology, and oncology. Specific candidates include AVD-104 and AVD-302 for dry eye and diabetic retinopathy, AVD-401 for retinoblastoma, AVD-601 for oncology, AVD-701 for neurology, and AVD-801 for fibrosis. Operations center on advancing these therapies through clinical development.
Who are the top competitors of Aviceda Therapeutics?
Aviceda Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Aviceda Therapeutics offer?
Aviceda Therapeutics offers Selective Ligands and Pipeline Programs.
Who are Aviceda Therapeutics's investors?
Aviceda Therapeutics has 12 investors. Key investors include Marshall Wace, abrdn, Orbimed, Blue Owl, and Enavate Sciences.